Welcome to our dedicated page for WORK Medical Technology Group SEC filings (Ticker: WOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The WORK Medical Technology Group LTD (WOK) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer in the medical devices sector. WORK Medical files annual reports on Form 20-F and current reports on Form 6-K, detailing its operations in developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through subsidiaries in China.
In these filings, investors can review information on WORK Medical’s product portfolio of medical consumables and equipment, its sales footprint across 34 provincial-level administrative regions in China, and the registration of 17 products with the U.S. Food and Drug Administration. Form 6-K reports provide updates on interim financial statements and management’s discussion and analysis, extraordinary general meetings and voting results, changes in independent auditors, and capital markets transactions such as registered direct offerings, at-the-market sales agreements, and pre-funded warrants.
Filings also describe share structure changes and Nasdaq listing matters, including approved share consolidations (reverse stock splits), increases in authorized share capital, and correspondence with Nasdaq regarding minimum bid price compliance and potential delisting determinations. These documents outline the reasons for share consolidations, effective dates, and post-consolidation share counts, giving context to changes in the company’s capital structure.
On Stock Titan, users can access WORK Medical’s Forms 6-K and 20-F as they are furnished to the SEC’s EDGAR system, along with AI-powered summaries that highlight key points such as financing terms, governance changes, and listing status updates. The filings page is also a reference point for tracking any future registration statements, prospectus supplements, and other transactional documents that the company incorporates by reference into its shelf registration statements.
WORK Medical Technology Group LTD (WOK) reports closing a private placement of new equity. The company issued 2,000,000 Class A ordinary shares at $1.00 per share and 50,000 Class B ordinary shares at $2.50 per share under securities purchase agreements with certain investors. The transaction closed on August 18, 2026 and generated aggregate gross proceeds of approximately $2,125,000, which the company intends to use for business expansion, working capital and general corporate purposes.
The shares were sold in an offshore private placement relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration, with investors representing they are not U.S. persons and no general solicitation used. After the closing, 4,416,569 Class A and 51,009 Class B ordinary shares were issued and outstanding.
WORK Medical Technology Group reported unaudited results for the six months ended March 31, 2026. Net revenue was $5,412,757, up 19.1% from $4,543,585, driven mainly by 18.1% growth in medical devices and 38.0% growth in mask sales, partly offset by reduced commodity trading.
Profitability weakened. Gross profit fell to $1,036,195 from $1,562,297, and gross margin declined to 19.1% from 34.4%, mainly due to China’s volume-based procurement policy and a higher mix of lower-margin products. General and administrative expenses rose 88.2% to $3,520,028, largely from higher professional fees, while government subsidies dropped sharply, resulting in a net loss of $3,461,214 versus a $29,425 loss a year earlier.
Cash flows from operations were an outflow of $9,907,075, reflecting higher working capital needs and expenses. The company invested in property and equipment and a 30% equity stake in Elefun, and acquired a non-controlling interest in a subsidiary. Liquidity was supported by $17,100,971 of net proceeds from an at-the-market offering and a $500,000 shareholder contribution. As of March 31, 2026, total assets were $48,309,506, including cash of $3,253,520, against short-term bank borrowings of $6,596,115 and total equity of $32,478,079.
WORK Medical Technology Group LTD reported that it entered into securities purchase agreements on August 4, 2026 for a private placement of 2,000,000 Class A ordinary shares at $1.00 per share and 50,000 Class B ordinary shares at $2.50 per share, for expected gross proceeds of approximately $2,125,000. Closing is subject to customary conditions and no shares have been issued yet. The transaction relies on Section 4(a)(2) and Regulation S exemptions, with transfer restrictions and restrictive legends.
The company also completed a 1-for-100 share consolidation of both Class A and Class B ordinary shares effective June 18, 2026, mainly to meet Nasdaq’s minimum bid-price requirement and reduce delisting risk. Outstanding shares changed from 241,754,604 (including 241,653,844 Class A) as of June 16, 2026 to approximately 2,417,548 after the consolidation. Authorized capital was restated to 160,000,000 Class A and 40,000,000 Class B shares at par value $0.001. An Amended and Restated Memorandum of Association became effective on May 14, 2026.
HRT Financial LP, a ten percent owner of WORK Medical Technology Group LTD, reported mixed trading in the company’s common stock. On June 17, 2026, it made an open-market purchase of 880,456 shares at $0.046 per share, bringing its holdings to 1,271,912 shares.
On June 18, 2026, HRT Financial LP executed an open-market sale of 136,665 shares at $3.87 per share, leaving it with 123,944 shares held directly. Overall, the filing shows a net increase of 743,791 shares in its position over these two days.
WORK Medical Technology Group LTD reported that major shareholder HRT Financial LP, a ten percent owner, both bought and sold its common stock in closely timed trades. On June 15, 2026, HRT Financial LP purchased 268,927 shares in an open-market transaction at $0.095 per share.
The next day, June 16, 2026, it executed an open-market sale of 2,904,567 common shares at $0.058 per share. After these transactions, HRT Financial LP directly held 391,456 WORK Medical common shares, with no derivative positions reported in this filing.
WORK Medical Technology Group LTD amendment to a Schedule 13G/A reports that Kelly Habbas certifies zero beneficial ownership of Class A Ordinary Shares (CUSIP G9767H125) as of the amendment. The filing provides the filer’s address in Frisco, TX and is signed on 06/16/2026.
HRT Financial LP, a 10% owner of WORK Medical Technology Group LTD, reported an open-market purchase of the company’s common stock. The firm bought 48,108 shares at $0.08 per share, bringing its direct holdings to 3,027,096 common shares after the transaction.
WORK Medical Technology Group (WOK) major shareholder HRT Financial LP, a ten percent owner, reported two open-market purchases of common stock. It bought 2,029,327 shares at $0.093 per share on June 11, 2026 and 1,765,384 shares at $0.099 per share on June 10, 2026, totaling 3,794,711 shares. After these transactions, HRT Financial LP held 2,978,988 common shares directly.
HRT Financial LP has reported its initial ownership in WORK Medical Technology Group LTD as a more than ten percent owner. The Form 3 shows direct holdings of 949,661 shares of Common Stock, establishing HRT Financial LP’s position but not reporting any recent purchases or sales.
HRT Financial LP, a ten percent owner of WORK Medical Technology Group, reported an open-market sale of 3,463,022 shares of Common Stock at $0.105 per share. After this transaction, HRT Financial LP reported holding zero shares directly.